# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: George H. W. Bush (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML018-SYN
- Date: 2026-05-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Douglas Whitford, MD
- Calendar frame: modern shifted

## Reason for visit

Post-hospital visit for new atrial fibrillation, with thyroid tests showing hyperthyroidism. **S**

## Historical basis

- George Herbert Walker Bush was born in Milton, Massachusetts, on June 12, 1924. **D**
- On May 4, 1991, he developed atrial fibrillation while running at Camp David; it presented as unusual fatigue during the run. He was flown to Bethesda Naval Hospital, where an electrocardiogram showed no abnormality except the irregular rhythm and a cardiac ultrasound showed no structural abnormality and normal heart function. Treatment began with digoxin. **D**
- On May 5, 1991, the White House said he still had atrial fibrillation, with no sign of heart damage or heart attack, and that procainamide had been added to digoxin; electrical cardioversion would be considered if the rhythm did not return to normal. **D**
- His normal rhythm returned late on May 5, atrial fibrillation recurred early on May 6, and cardioversion was judged unnecessary because his response to medication was encouraging. He was discharged on May 6 and was in normal sinus rhythm later that day, on digoxin and procainamide. **D**
- Later in the same week he was diagnosed with Graves' disease. **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- New irregular heartbeat that began as unusual tiredness on a run; wants to know whether he can keep running. **S**
- Wants to get back to a full working schedule and to exercise as soon as it is safe. **S**

## Strengths and supports

- Supports: spouse, adult children, and close colleagues and friends **S**

## Medications and allergies

- Metoprolol succinate extended-release 50 mg oral tablet, one tablet by mouth daily (started in hospital) **S**
- Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital) **S**
- Methimazole 10 mg oral tablet, two tablets (20 mg) by mouth daily **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- May 4, 1991: Atrial fibrillation that began as unusual fatigue while running; hospital stay of two days, with normal ECG apart from the rhythm and a normal cardiac ultrasound; sinus rhythm restored on medication without cardioversion **D** (CLM-0002, CLM-0003, CLM-0004)

## Procedures and immunizations

- 2026-05-05 to 2026-05-05: Transthoracic echocardiogram in hospital: normal chamber sizes, including the left atrium, normal valves, and left ventricular ejection fraction 60 percent **S**
- 2026-05-08 to 2026-05-08: 12-lead ECG at intake: sinus rhythm at 88 per minute, normal intervals, no ischemic change **S**
- 2025-10-14: High-dose influenza vaccine, 2025-2026 season **S**
- 2024-10-08: Pneumococcal conjugate vaccine PCV20 **S**
- 2022-03-15: Recombinant zoster vaccine, two-dose series completed **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

TSH: 0.005 mIU/L (low); Free T4: 3.6 ng/dL (high); Total T3: 280 ng/dL (high); TSH receptor antibody: 8.2 [IU]/L (high); White cell count: 6.8 10*3/uL; Absolute neutrophil count: 3.9 10*3/uL; Hemoglobin: 14.8 g/dL; ALT: 32 U/L; Creatinine: 0.92 mg/dL; eGFR: 87 mL/min/1.73 m²; Potassium: 4.2 mmol/L. All results are synthetic.

BP 142/68 mmHg; pulse 88 bpm; respirations 16/min; temperature 37.1 °C; oxygen saturation 98% on room air; weight 86 kg; BMI 24.3 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, cheerful, and talkative; Mood good. Functional status: At intake, independent in all activities but more tired than usual on runs, with some weight loss despite a good appetite; Back to running three miles four days a week without palpitations by the four-month review. Physical examination is intentionally limited. **S**

## Assessment

1. Paroxysmal atrial fibrillation, first detected four days before intake while running, triggered by hyperthyroidism; CHA2DS2-VASc 1; synthetic modern episode linked to his documented atrial fibrillation; status draft. **S**
2. Graves' disease with hyperthyroidism; synthetic modern diagnosis linked to his documented Graves' disease; status draft. **S**

## Plan

- Rate control with metoprolol succinate 50 mg daily; no antiarrhythmic drug or cardioversion while thyrotoxic, because most thyrotoxic atrial fibrillation reverts once thyroid levels are normal; taper the beta-blocker once he is no longer thyrotoxic. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Stroke-risk and bleeding-risk scoring (CHA2DS2-VASc 1 for age 65 to 74; HAS-BLED 1 for age over 65) with a shared decision to continue apixaban 5 mg twice daily while thyrotoxic, then reassess once sustained sinus rhythm is confirmed after he is no longer thyrotoxic. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Methimazole 20 mg daily after a baseline blood count and liver tests, with written advice to stop it and call at once for fever, sore throat, mouth ulcers, jaundice, or dark urine; stop three days before radioactive iodine. Guideline: 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) **S**
- Endocrinology consultation to confirm Graves' disease, assess the eyes, and choose definitive treatment (radioactive iodine, long-term methimazole, or surgery). Guideline: 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) **S**
- Atrial fibrillation monitoring at every visit (heart rate and rhythm, blood pressure, weight, symptoms, activity, alcohol, tobacco), ECG when indicated, echocardiogram at diagnosis, CHA2DS2-VASc and HAS-BLED yearly, creatinine and blood count at baseline and yearly on apixaban, and sleep apnea screening at diagnosis and yearly. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Return to running in steps once the heart rate is controlled, aiming for about 210 minutes a week of moderate to vigorous activity; limit alcohol to no more than one drink a day. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**

## Guideline basis

- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023), American College of Cardiology, American Heart Association, American College of Chest Physicians, and Heart Rhythm Society (Circulation 2024;149(1):e1-e156)
- 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016), American Thyroid Association (Thyroid 2016;26(10):1343-1421)
- CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026), Aether Forge
